Can erythropoietin eradicate red cell transfusions in the critically ill?

Critical Care Medicine

Volumn 34, Issue 9, 2006, Pages 2490-2491

  Hébert, Paul C ^a   Fergusson, Dean A ^a  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; IRON; PLACEBO; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; CHRONIC DISEASE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CRITICAL ILLNESS; DRUG COST; DRUG EFFICACY; EDITORIAL; ERYTHROCYTE TRANSFUSION; HUMAN; INTENSIVE CARE; PRIORITY JOURNAL; THROMBOSIS; TREATMENT PLANNING;

ANEMIA; CRITICAL ILLNESS; ERYTHROCYTE TRANSFUSION; ERYTHROPOIETIN, RECOMBINANT; HEMATINICS; HUMANS; INTENSIVE CARE UNITS; RANDOMIZED CONTROLLED TRIALS;

EID: 33747503915     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000235671.59923.CF     Document Type: Editorial

References (18)

1. Rodriguez RM, Corwin HL, Gettinger A, et al: Nutritional deficiencies and blunted erythropoietin response as causes of the anemia of critical illness. J Crit Care 2001; 16:36-41
2. Vincent JL, Baron J-F, Reinhart K, et al: Anemia and blood transfusion in critically ill patients. JAMA 2002; 288:1499-1507
3. Corwin HL, Gettinger A, Pearl RG, et al: The CRIT Study: Anemia and blood transfusion in the critically ill: Current clinical practice in the United States. Crit Care Med 2004; 32:39-52
4. Rogiers P, Zhang H, Leeman M, et al: Erythropoietin response is blunted in critically ill patients. Intensive Care Med 1997; 23:159-162
5. Corwin HL, Krantz SB: Anemia of the critically ill: "Acute" anemia of chronic disease. Crit Care Med 2000; 28:3098-3099
6. Gabriel A, Kozek S, Chiari A, et al: High-dose recombinant human erythropoietin stimulates reticulocyte production in patients with multiple organ dysfunction syndrome. J Trauma 1998; 44:361-367
7. Frede S, Fandrey J, Pagel H, et al: Erythropoietin gene expression is suppressed after lipopolysaccharide or interleukin-1 beta injections in rats. Am J Physiol 1997; 273:t-71
8. Jelkmann W: Proinflammatory cytokines lowering erythropoietin production. J Interferon Cytokine Res 1998; 18:555-559
9. Silver M, Corwin MJ, Bazan A, et al: Efficacy of recombinant human erythropoietin in critically ill patients admitted to a long-term acute care facility: A randomized, double-blind, placebo-controlled trial. Crit Care Med 2006; 34:2310-2316
10. Corwin HL, Gettinger A, Rodriguez RM, et al: Efficacy of recombinant human erythropoietin in the critically ill patient: A randomized, double-blind, placebo-controlled trial. Crit Care Med 1999; 27:2346-2350
11. Corwin HL, Gettinger A, Pearl RG, et al: Efficacy of recombinant human erythropoietin in critically ill patients: A randomized controlled trial. JAMA 2002; 288:2827-2835
12. Carson JL: Should patients in intensive care units receive erythropoietin? JAMA 2002; 288:2884-2886
13. Hebert PC, Wells G, Blajchman MA, et al: A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care: Transfusion requirements. Critical Care Investigators, Canadian Critical Care Trials Group (erratum appears in 1999; 340:1056). N Engl J Med 1999; 340:409-417
14. Hebert PC, Yetisir E, Martin C, et al: Is a low transfusion threshold safe in critically ill patients with cardiovascular diseases? [see comment]. Crit Care Med 2001; 29:227-234
15. Laupacis A, Fergusson D: Erythropoietin to minimize perioperative blood transfusion: A systematic review of randomized trials. Transfus Med 1998; 8:309-317
16. Corwin HLM, Hebert PM: Avoiding a blood transfusion: How much is it worth? Crit Care Med 2005; 33:672-674
17. Corwin HL, Parsonnet KC, Gettinger A: RBC transfusion in the ICU: Is there a reason? Chest 1995; 108:767-771
18. National Institutes of Health. Clinical Trials. 2004 (available at http://clinicaltrials.gov/ct/gui)